Isomorphic Labs is a London-based company that uses artificial intelligence for drug discovery. The company was founded by Demis Hassabis, who also serves as its CEO. Isomorphic Labs was established as a spin-off from Alphabet Inc.'s AI research lab, DeepMind, which Hassabis also founded and currently heads.
The company leverages DeepMind's AlphaFold technology to predict protein structures and molecule interactions in the human body, enabling researchers to identify new target pathways for drug delivery. Isomorphic Labs aims to revolutionize the drug discovery process by utilizing an AI-first approach, ultimately seeking to understand the fundamental mechanisms of life.
Demis Hassabis Joshua Bambrick Alexey Cherepanov Miles Congreve Caroline M R Low Pascal Savy Adrian Stecula Catherine Tong Sergei Yakneen Max Jaderberg
Isomorphic Labs was incorporated on February 4, 2021, and officially announced on November 5, 2021. In December 2022, the company expanded its operations by establishing a second office in Lausanne, Switzerland.
In January 2024, Isomorphic Labs formed partnerships with prominent pharmaceutical companies Novartis AG and Eli Lilly and Company. These collaborations focus on AI drug discovery and research, with the potential to be worth nearly $3 billion, excluding future drug sales royalties.
Isomorphic Labs builds upon DeepMind's AlphaFold technology, specifically utilizing AlphaFold 3. This AI model can predict the structure and interactions of various molecules involved in biological processes, including proteins, DNA, RNA, and drug-related chemicals. AlphaFold 3 represents a significant advancement over its predecessor, AlphaFold 2, by expanding its capabilities beyond just protein structure prediction.